SAVANNAH, Ga., April 7 /PRNewswire-FirstCall/ -- Health Discovery Corporation (BULLETIN BOARD: HDVY) today announced that David Cooper, M.D., Ph.D., President and Chief Medical Officer of Health Discovery Corporation, was one of the presenters at the Southern California Investment Association conference on Saturday April 3rd which was held in Orange County, CA. Dr. Cooper discussed the status of Health Discovery Corporation, a genomic/proteomic/biotechnology company focused on biomarker and pathway discovery for diagnostic markers and drug targets.
He indicated that the company is proceeding well with recently signed agreements with MD Anderson Cancer Center, Stanford University and the University of Miami. These agreements, which provide joint ownership of the biomarker discovery and/or rights to obtain worldwide exclusive licenses to the discoveries, are focusing specifically on Prostate Cancer, Leukemia, AIDS Related Dementia and Lymphatic Insufficiency. Additional relationships are to be announced shortly.
He expects the Company to be profitable within about 18 months as their products and client list continues to grow. Dr. Cooper indicated that whereas most companies in the genomic/proteomic space are raising upwards of $100 million to fund their research, Health Discovery Corporation's expected capital requirements will be small in comparison to several of its competitors in this space because HDC identifies patient-specific commercially important clinical problems and then establishes relationships with diagnostic and pharmaceutical companies world-wide to facilitate a solution, whereas, other companies focus on general discovery without a specific patient or illness in mind.
Health Discovery Corporation is a systems biology oriented biomarker and pathway discovery company, which uses proprietary advanced mathematical platforms, such as Fractal Genomics Modeling (FGM) techniques, to help identify and characterize diagnostic targets and therapeutic candidates. Focusing on disease vs. normal, within complex genomic, proteomic and clinical data sets, Health Discovery Corporation was established to provide pharmaceutical and diagnostic companies with a broad range of analytical and decision support solutions to accelerate effective diagnostic and drug discovery. Founded in September 2003, the Company has offices in Texas, Georgia, and California. For more information contact Robert S. Braswell IV of Health Discovery Corporation +1-866-953-9031 or Info@healthdiscoverycorp.com.
This news release contains "forward-looking statements" within the meaning of Section 27a of the Securities Acts of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct.
More information: http://www.healthdiscoverycorp.com/
This release was issued on behalf of the above organization by Send2Press(TM), a unit of Neotrope(R). http://www.send2press.com/
Health Discovery CorporationCONTACT: Robert S. Braswell IV of Health Discovery Corporation,+1-866-953-9031